NanoSanguis Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$247K
- Investors
-
5
NanoSanguis General Information
Description
Developer of red blood cell substitutes designed to offer an alternative to natural blood. The company's substitutes use a biotechnology method for producing synthetic oxygen carrier that is stable for at least one year of storage and is developing blood substitutes based on full physiological, buffered fluid composed of balanced minerals compatible with the human organism, enabling clinics to meet the rapidly increasing blood deficit.
Contact Information
Website
www.nanosanguis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
- Rakowiecka 36
- Warsaw, 02-532
- Poland
NanoSanguis Timeline
NanoSanguis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 09-Nov-2020 | $247K | Completed | Generating Revenue | ||
| 2. Grant | 16-Aug-2019 | 00000 | Completed | Generating Revenue | ||
| 1. Early Stage VC | 01-Jan-2015 | Completed | Startup |
NanoSanguis Patents
NanoSanguis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019367331-A1 | New ammonium salts of fluorinated organic acids, method of their synthesis and application | Pending | 26-Oct-2018 | 00000000 | |
| CA-3117605-A1 | New ammonium salts of fluorinated organic acids, method of their synthesis and application | Pending | 26-Oct-2018 | 00000000 | |
| EP-3870564-A2 | New ammonium salts of fluorinated organic acids, method of their synthesis and application | Pending | 26-Oct-2018 | 00000000 | |
| US-20210369846-A1 | New ammonium salts of fluorinated organic acids, method of their synthesis and application | Pending | 26-Oct-2018 | A61P7/08 |
NanoSanguis Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Izabela Gałązka | Chief Executive Officer | ||
| Agata Stefanek Ph.D | Co-Founder & Executive | ||
| Tomasz Ciach | Co-Founder & Member of Supervisory Board |
NanoSanguis Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Maciej Sadowski | Startup Hub Poland | Member of the Supervisory Board | 000 0000 |
| Marek Borzestowski | Giza Polish Ventures | President of the Supervisory Board | 000 0000 |
NanoSanguis Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
NanoSanguis Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| EuroNanoMed III | Other | Minority | 000 0000 | 000000 0 | |
| European Regional Development Fund (Brandenburg) | Sovereign Wealth Fund | 000 0000 | 000000 0 | ||
| Giza Polish Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| StarFinder | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Startup Hub Poland | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |